CALCA and migraine disorder: Future real-world studies may shed additional light on the clinical use of CGRP pathway mAbs for patients with comorbidities or AMO who did not respond to an initial CGRP pathway–targeted mAb and need to switch between treatments within this class or for those who require concomitant treatment with another acute or preventive migraine medication.